Streetbeat News

MDGL

Madrigal Pharmaceuticals, Inc.

https://www.madrigalpharma.com

Industry

Biotechnology

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Open

328.50

Mkt cap

7.7B

Volume

382K

High

348.35

P/E Ratio

-15.90

52-wk high

377.46

Low

326.70

Div yield

N/A

52-wk low

189.00

Citigroup analyst David Lebovitz has maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) and increased the price target from $382 to $389.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 3:10 pm

Blend Labs, Inc. (BLND) reported Q4 financial results with a loss of 9 cents per share and sales of $36.10 million, causing its shares to jump 24.3%. Other stocks like Cardlytics, Inc. (CDLX), American Vanguard Corporation (AVD), and Madrigal Pharmaceuticals, Inc. (MDGL) also saw significant gains following their earnings reports or other positive news. The overall market was down, with the Dow Jones index falling around 100 points.

Portfolio Pulse from Avi Kapoor

March 15, 2024 | 2:25 pm

In Friday's pre-market session, several healthcare stocks showed significant movement. Better Therapeutics (BTTX) led the gainers with an 85.4% increase, while SELLAS Life Sciences Gr (SLS) experienced the largest drop among the losers, decreasing by 33.5%. Other notable movers include Madrigal Pharmaceuticals (MDGL) with a 22.34% increase and Lucy Scientific Discovery (LSDI) with a 25.53% decrease. The movements were attributed to various factors including quarterly earnings reports.

Portfolio Pulse from Benzinga Insights

March 15, 2024 | 1:06 pm

Madrigal Pharmaceuticals (MDGL) shares surged 28% following FDA approval of Rezdiffra for NASH treatment. Cardlytics (CLDX) shares jumped 53% after reporting strong Q4 revenue and optimistic Q1 guidance, with Needham maintaining a Buy rating and raising the price target. Adobe (ADBE) shares fell 12% due to disappointing Q1 results and weak future guidance, alongside multiple firms reducing their price targets.

Portfolio Pulse from ryanfaloona@benzinga.com

March 15, 2024 | 12:36 pm

Madrigal Pharmaceuticals' stock is trading higher following the FDA approval of Rezdiffra, a treatment for noncirrhotic NASH with moderate to advanced liver fibrosis.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:32 pm

Oppenheimer analyst Jay Olson maintains an Outperform rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $320 to $375.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:27 pm

Canaccord Genuity analyst Edward Nash maintains a Buy rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $338 to $377.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 12:16 pm

Cardlytics, Inc. (CDLX) shares surged by approximately 37% in pre-market trading after reporting Q4 earnings that exceeded expectations, with adjusted earnings of 14 cents per share against estimates of 12 cents. The company also forecasted Q1 revenue between $70 million and $73 million, surpassing the expected $66.46 million. Other stocks showed significant movement in pre-market trading, with notable gainers including Fisker Inc. (FSR), Madrigal Pharmaceuticals, Inc. (MDGL), and American Vanguard Corporation (AVD), among others. Conversely, companies like Kopin Corporation (KOPN), Smartsheet Inc. (SMAR), and Adobe Inc. (ADBE) experienced declines.

Portfolio Pulse from Avi Kapoor

March 15, 2024 | 12:13 pm

B. Riley Securities analyst Mayank Mamtani upgrades Madrigal Pharmaceuticals (MDGL) from Sell to Neutral and increases the price target from $155 to $270.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 11:55 am

JMP Securities analyst Jonathan Wolleben maintains an Outperform rating on Madrigal Pharmaceuticals (MDGL) and raises the price target from $351 to $397.

Portfolio Pulse from Benzinga Newsdesk

March 15, 2024 | 11:03 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.